Clinical studies suggest that the novel, targeted agent ibrutinib shows real potential is a safe, effective, treatment for adults with chronic lymphocytic leukemia and for patients with mantle cell lymphoma.
Clinical studies suggest that the novel, targeted agent ibrutinib shows real potential is a safe, effective, treatment for adults with chronic lymphocytic leukemia and for patients with mantle cell lymphoma.